Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A.

Wang W, Zhang H, Liu S, Kim CK, Xu Y, Hurley LA, Nishikawa R, Nagane M, Hu B, Stegh AH, Cheng SY, Cheng C.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8366-8371. doi: 10.1073/pnas.1701289114. Epub 2017 Jul 17.

2.

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH.

Cell Rep. 2017 May 30;19(9):1858-1873. doi: 10.1016/j.celrep.2017.05.014.

3.

Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.

Sita TL, Kouri FM, Hurley LA, Merkel TJ, Chalastanis A, May JL, Ghelfi ST, Cole LE, Cayton TC, Barnaby SN, Sprangers AJ, Savalia N, James CD, Lee A, Mirkin CA, Stegh AH.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4129-4134. doi: 10.1073/pnas.1702736114. Epub 2017 Apr 3.

4.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

5.

miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.

Kouri FM, Ritner C, Stegh AH.

Cell Cycle. 2015;14(24):3794-800. doi: 10.1080/15384101.2015.1093711.

6.

Ribozyme-Spherical Nucleic Acids.

Rouge JL, Sita TL, Hao L, Kouri FM, Briley WE, Stegh AH, Mirkin CA.

J Am Chem Soc. 2015 Aug 26;137(33):10528-10531. doi: 10.1021/jacs.5b07104. Epub 2015 Aug 14.

7.

Preface.

Mirkin CA, Meade TA, Petrosko SH, Stegh AH.

Cancer Treat Res. 2015;166:v-vii. No abstract available.

PMID:
26072528
8.

Therapeutic applications of spherical nucleic acids.

Barnaby SN, Sita TL, Petrosko SH, Stegh AH, Mirkin CA.

Cancer Treat Res. 2015;166:23-50. doi: 10.1007/978-3-319-16555-4_2. Review.

PMID:
25895863
9.

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.

Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH.

Genes Dev. 2015 Apr 1;29(7):732-45. doi: 10.1101/gad.257394.114.

10.

NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.

Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD.

Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13.

11.

HOIL-1L functions as the PKCĪ¶ ubiquitin ligase to promote lung tumor growth.

Queisser MA, Dada LA, Deiss-Yehiely N, Angulo M, Zhou G, Kouri FM, Knab LM, Liu J, Stegh AH, DeCamp MM, Budinger GR, Chandel NS, Ciechanover A, Iwai K, Sznajder JI.

Am J Respir Crit Care Med. 2014 Sep 15;190(6):688-98. doi: 10.1164/rccm.201403-0463OC.

12.

Bcl2L13 is a ceramide synthase inhibitor in glioblastoma.

Jensen SA, Calvert AE, Volpert G, Kouri FM, Hurley LA, Luciano JP, Wu Y, Chalastanis A, Futerman AH, Stegh AH.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5682-7. doi: 10.1073/pnas.1316700111. Epub 2014 Mar 31.

13.

Spherical nucleic acids for precision medicine.

Mirkin CA, Stegh AH.

Oncotarget. 2014 Jan 15;5(1):9-10. No abstract available.

14.

Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH.

Sci Transl Med. 2013 Oct 30;5(209):209ra152. doi: 10.1126/scitranslmed.3006839.

15.

Toward personalized cancer nanomedicine - past, present, and future.

Stegh AH.

Integr Biol (Camb). 2013 Jan;5(1):48-65. doi: 10.1039/c2ib20104f.

16.

The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.

Kouri FM, Jensen SA, Stegh AH.

ScientificWorldJournal. 2012;2012:838916. doi: 10.1100/2012/838916. Epub 2012 Feb 14. Review.

17.

Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

Stegh AH.

Expert Opin Ther Targets. 2012 Jan;16(1):67-83. doi: 10.1517/14728222.2011.643299. Epub 2012 Jan 12. Review.

18.

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA.

Nature. 2011 Feb 10;470(7333):269-73. doi: 10.1038/nature09677. Epub 2011 Feb 2.

19.

Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.

Stegh AH, DePinho RA.

Cell Cycle. 2011 Jan 1;10(1):33-8. Epub 2011 Jan 1. Review.

20.

Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor.

Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, Protopopov A, Chin L, Depinho RA.

Genes Dev. 2010 Oct 1;24(19):2194-204. doi: 10.1101/gad.1924710. Epub 2010 Sep 13.

Supplemental Content

Loading ...
Support Center